Respiratory and pulmonary clinical trials are becoming increasingly complicated due to various factors, including their prevalence in pediatric populations, new and updated guidelines, and side effects related to some of the most common therapies.
Respiratory Clinical Research: How to Navigate Therapeutic and Operational Challenges discusses clinical research insights from the 2022 ERS International Congress that will most impact study design and operationalization for various respiratory therapies and indications. Click below to download our new white paper and discover insights into:
- Research updates and challenges within asthma, including possible mechanisms of the disease, target receptors, and the role of biologics in disease management and diagnostic approaches
- Corticosteroid misuse or overuse in respiratory conditions
- Insights into the impact of COVID-19 and respiratory disease, further complicating pre-existing challenges to pulmonary disease treatment
View a sneak peek below
The European Respiratory Society (ERS) International Congress 2022 took place on September 4-6 in Barcelona, Spain. It brought together the world’s respiratory experts to present and discuss the latest scientific and clinical advances in respiratory medicine, including respiratory tract infections, asthma, chronic obstructive pulmonary disease (COPD), pulmonary fibrosis, and respiratory tract cancers. This white paper will discuss the presentations and abstracts with the most significant advances in diagnostic and treatment approaches in various indications and how they can potentially influence clinical trials.
The ERS International Congress 2022 was the organization’s first annual meeting after a two-year pause caused by the COVID-19 pandemic, with over 10,000 delegates present on-site and 5,000 participating virtually. Over 3,500 poster sessions, 500 presentations, and 300 industry sessions covered all aspects of respiratory diseases.
There was a focus on recent updates within asthma research, including the immunology and possible mechanisms of the disease, target receptors, and the role of biologics in disease management and diagnostic approaches, particularly in pediatric asthma. The presenters also discussed the rationale for the early administration of effective antibiotics to treat pneumonia, a new guideline on the management of interstitial pulmonary fibrosis, and approaches to diagnosis and treatment of severe community-acquired pneumonia and respiratory syncytial infection.
Discover Respiratory Insights in our Latest Whitepaper
ABOUT THE AUTHOR
Maxim Kosov, MD, PH.D.
PSI SENIOR MEDICAL ADVISOR
Maxim Kosov, MD, Ph.D., is a Senior Medical Advisor at PSI CRO AG (USA). He graduated from Pediatric Medical Academy in Saint-Petersburg, Russia, in 1993 and worked as an intensive care physician in neonatal intensive care units of several major hospitals. He completed an international fellowship in neonatology at Albany Medical College, NY, USA, in 1996. In parallel with clinical work, Maxim was an Assistant Professor of the Faculty of Anesthesiology and Intensive Care at Saint-Peterburg Pediatric Medical Academy.
He joined PSI in 2004 and acted as a Medical Monitor in more than 60 clinical trials in various indications. He is the author/co-author of more than 50 publications and presented his research works at numerous international meetings and congresses, including annual European Respiratory Society (ERS) meetings in Berlin (2002), Stockholm (2002), and Drug Information Association (DIA) Congress in Hamburg (2016). He is a member of ASCO.
ABOUT PSI CRO
PSI CRO is a privately-owned, full-service clinical research organization (CRO) operating globally. PSI’s global reach supports clinical trials across multiple countries and continents and specializes in the planning and execution of global pivotal registration clinical trials. With an exceptionally high repeat and referral business rate combined with minimal staff turnover, PSI is committed to being the best CRO in the world as measured by its employees, customers, investigators, and vendors.
Global headquarters are based Switzerland at 113a Baarerstrasse, Zug 6300. www.psi-cro.com